NCT06503692 Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis
| NCT ID | NCT06503692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | DK Medical Technology (Suzhou) Co., Ltd. |
| Condition | Arteriovenous Graft Stenosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2024-08-13 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2024-08-13 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, prospective, randomized controlled clinical study. Patients with hemodialysis arteriovenous graft fistula stenosis will be recruited to explore whether the scoring balloon is superior to the high pressure balloon in treating such lesions, so as to provide a basis for optimizing the treatment of such lesions. This study will be conducted in seven (7) clinical trial institutions, with a total of 140 subjects included. After randomization, the subjects will use either the scoring balloon dilatation catheter, developed and produced by DK Medical Technology Co., Ltd., or the peripheral balloon dilatation catheter for surgical treatment. Clinical follow-up will be carried out within 5 days, 3 months, 6 months, and 12 months after the procedure.
Eligibility Criteria
Inclusion Criteria: 1. Hemodialysis patients aged ≥18 and ≤80 years old, (Note: Hemodialysis patients in Singapore aged ≥ 21 and ≤80 years old); 2. AVG is mature and has successfully completed at least one hemodialysis treatment; 3. The target lesion is located in the AVG return vein and the venous side anastomosis; 4. The degree of stenosis of the target lesion is ≥50% (DSA visual inspection), and one of the following clinical indicators exists at the same time: Physical examination abnormalities include: open collateral veins, ipsilateral limb edema, changes in pulse characteristics, abnormal tremors, abnormal murmurs, etc.; Dialysis abnormalities include: increased venous pressure, new puncture difficulties, aspiration of thrombi, inability to reach target dialysis blood flow, prolonged haemostasis time after needle removal for 3 consecutive times, unexplained decrease in dialysis dose Kt/V (\>0.2 units), decrease in brachial artery blood flow (brachial artery blood flow \<650ml/min or decreased by 20% compared with the previous follow-up visit), etc. 5. The target lesion is primary or restenotic, consisting of one or more series of lesions, and the reference blood vessel diameter of the target lesion is between 4.0-8.0mm, and the total length of the target lesion is ≤80mm ; 6. The patient voluntarily signs the informed consent form. Exclusion Criteria: 1. The target lesion is located in the feeding artery, arterial anastomosis, artificial blood vessel puncture site, cephalic venous arch, thoracic outlet or central vein; 2. A stent has been implanted in any part of the access or there is ipsilateral central vein stenosis or occlusion that affects the function of the access; 3. Severely calcified lesions that are not expected to be dilatable with balloons; 4. Acute thrombosis or chronic total occlusion of AVG occurred at the time of enrolment; 5. The target lesion or any part of the vascular access has received PTA treatment within the last month; 6. There are thicker branch veins in the vein opening of the end-to-side anastomosis; 7. Patients who have undergone major surgical treatment within 30 days before inclusion in the study; 8. Patients known to be allergic to or intolerant to contrast media; 9. Patients receiving glucocorticoids or immunosuppressants; 10. The patient's life expectancy is less than 1 year; 11. Patients planning kidney transplantation or switching to peritoneal dialysis; 12. The degree of stenosis in the puncture point area is \>50%； 13. Patients with infection or other medical conditions that make the investigator think they are not suitable to participate in this study; 14. Those who have participated in clinical trials of other drugs or devices but have not completed them.
Contact & Investigator
Pei Wang, MD
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital of Zhengzhou University
Frequently Asked Questions
Who can join the NCT06503692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Arteriovenous Graft Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06503692 currently recruiting?
Yes, NCT06503692 is actively recruiting participants. Contact the research team at wangpei146@hotmail.com for enrollment information.
Where is the NCT06503692 trial being conducted?
This trial is being conducted at Beijing, China, Guangzhou, China, Shenzhen, China, Zhengzhou, China and 3 additional locations.
Who is sponsoring the NCT06503692 clinical trial?
NCT06503692 is sponsored by DK Medical Technology (Suzhou) Co., Ltd.. The principal investigator is Pei Wang, MD at The First Affiliated Hospital of Zhengzhou University. The trial plans to enroll 140 participants.